Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study

Table 1

Characteristics of patients.

	Exenatide	Dulaglutide	Insulin glargine	Placebo
Cases ()	19	19	10	17
Male/female ()	9/10	11/8	7/3	9/8	0.694
Age (years)					0.060
Body weight (kg)					0.780
BMI (kg/m^2)					0.337
HbA1c (%)					0.265
TC (mmol/L)					0.082
TG (mmol/L)					0.471
BUN (mmol/L)					0.963
Scr (μmol/L)					0.898
BMD-L1 (g/cm^2)					0.287
BMD-L2 (g/cm^2)					0.747
BMD-L3 (g/cm^2)					0.673
BMD-L4 (g/cm^2)					0.830
BMD-L1-L4 (g/cm^2)					0.689
BMD-femoral neck (g/cm^2)					0.090
BMD-total hip (g/cm^2)					0.131

Abbreviation: BMI: body mass index; HbA1c: glycosylated hemoglobin; TC: total cholesterol; TG: triglycerides; BUN: blood urea nitrogen; Scr: serum creatinine; BMD-L: bone mineral density of lumbar vertebrae; BMD-femoral neck: bone mineral density of femoral neck; BMD-total hip: bone mineral density of total hip; data shown as .